It’s hard to ignore a news release that claims a reconstructive breast surgery technique is “innovative” and “has the potential to be a ‘game-changer,'” as does this one from The Valley Hospital in Ridgewood, New Jersey.
The release focuses on the outcome of one 43-year-old woman who received the hospital system’s first attempt at the surgery and is quoted extensively in the release. The procedure in question is available to some women who get a mastectomy following diagnosis, yet want an implant to recreate the appearance of their breast or breasts. After the breast tissue is removed, a balloon-like sac is temporarily placed in the void left behind and gradually filled with fluid. This prepares the skin and muscles nearby for a permanent implant, which is typically inserted a couple of months later for “an excellent aesthetic outcome.”
This all sounds wonderful, but our review team (which includes a breast surgeon) thought the release was nearly devoid of crucial context. It doesn’t adequately discuss costs, risks, evidence, or alternatives, and it doesn’t make clear how this procedure differs from similar, more common implant techniques. It also trumpets the outcome of one woman, whose experience with the procedure — while extremely positive — may not hold true for many women who elect to have mastectomies.
At best, this release is an incomplete advertisement.
Electing to have breast surgery is often an extraordinarily difficult decision: Every patient’s cancer, her risks, and her needs are different. And while it’s nice to have options for reconstructive breast surgery — a topic that’s important to women affected by breast cancer — the advantages or disadvantages of one procedure over another seems to become less clear as more techniques become available. That’s why it’s increasingly important for medical institutions that promote the latest-and-greatest cosmetic procedure make clear its place in a cornucopia of alternatives, and adequately discuss the risks of surgeries that may have little or no bearing on survival or other critical outcomes.
No dollar signs here. However, not including a mastectomy (anywhere from $15,000 to $55,000 or more), tissue-expander breast surgeries typically cost about $40,000 per breast. But if there are any complications, those costs can skyrocket due to additional surgeries and other medical costs.
The benefits are described — “diminished post-operative pain, quicker recovery time, improved mobility, and an excellent aesthetic outcome” — but not quantified, neither alone nor in comparison to other options.
How much is pain reduced by this procedure? How much faster is the recovery time? How much better can women get around? What constitutes “excellent” when it comes to the look of a reconstructed breast? We aren’t told.
Even if the release had quantified the results or made a comparison to other techniques, this is a report of one procedure in one patient. It is not possible to make general statements about the benefits of a procedure when only one procedure has been performed.
As a 2013 New York Times Well blog post highlights, about one-in-four nipple-sparing surgeries (promoted by this release) lead to dead tissue “in the areola or in nearby skin” — and additional surgeries to remove that dead tissue.
The risks or necessity of mastectomy and reconstructive breast surgery aren’t mentioned, either. Mastectomies (as compared to lumpectomies or avoiding surgery altogether) may not lead to better outcomes for many women. Also, implants can leak, cause infections, and lead to other complications. We’re also not told how radiation and chemotherapy — two extremely common treatments in conjunction with breast cancer surgeries — affect results.
The one saving grace of this release is its last word, which makes a case for approaching each woman’s diagnosis and treatment on an individual basis.
Throughout the release, we get an earful about cause-and-effect relationship: If you do get tissue expander before, then you’ll heal faster, suffer less, and look better.
But all we get is a vague mention to “ongoing research.” What and where are these studies? At the very least, how are outcomes measured? Who is this procedure appropriate or inappropriate for?
The lack of key details that support the release’s claims is a major oversight. This is a procedure not commonly performed, and more study is needed to identify best candidates for the procedure as well as to evaluate the complications and long term results.
Descriptions of pain and long recovery periods are found in this release. But that seems essential to the nature of this procedure, which aims to reduce these and other problems.
The Valley Breast Center is listed at the end of the release. But due to the overwhelmingly positive comments from the patient who received the procedure, it would have helped to make clear whether or not she was compensated in any form by the hospital system.
Options for reconstructive breast surgeries are as numerous as they are nuanced, depending on the needs of the patient. However, none of them — one-stage implant surgeries, muscle flap surgeries, etc. — get even a passing mention.
In the context of this procedure, it would have been helpful to clear up the alternatives, including the more-common procedure of getting an implant beneath the chest muscle (where it’s less likely to cause complications).
It should always be stressed that there is no one-size-fits-all approach to breast cancer reconstruction. Factors taken into account include the patient’s constitution, other medical problems, location of the cancer in the breast, type of cancer, need for preoperative or postoperative chemotherapy, need for radiation therapy, and patient preferences for cosmetic outcome. In addition, extensive discussion needs to be held regarding the potential complications of each reconstructive approach.
We’re told The Valley Hospital performed this surgery, and — by implication of going through the effort of issuing a news release — we have to assume the hospital plans to perform this surgery again for patients who qualify. However, that isn’t made clear.
This is definitely not a new technique. However it needs to be stressed that there are very good reasons why it is not commonly performed, and this release does not discuss any of them. The novelty is essentially lost in this release — the most we’re told is that this is a “variation of a standard technique.”
Almost all tissue-expanding breast surgeries place a balloon-like sac beneath chest muscles and on top of the ribs, where they’re better held in place (and less likely to protrude through surgical cuts).
The procedure described here places the implant on top of the chest muscles — right below the skin. Breast surgeons typically avoid this because the breast skin alone might not be able to support a saline-filled sac after an aggressive surgery, even if filed gradually over weeks.
And as much as this release tries to make the procedure seem new, it’s not; it just appears to be new within this particular corner of New Jersey.
Hyped terms like “innovative” and phrases such as “has the potential to be a ‘game-changer'” are found throughout this release — and there’s almost nothing to back them up.
Systematic, Criteria-Driven
Puleeeeease... this 'game changer' weight loss drug causes more nausea and vomiting than a placebo. Some game, some change. My friend Gary would spank you for using the eighth word medical reporters should never, ever use. @garyschwitzer @thackerpd
https://www.healthnewsreview.org/toolkit/just-journalists-writing-tips-case-studies/7-words-and-more-you-shouldnt-use-in-medical-news/ https://twitter.com/OttawaCitizen/status/1361426796126830597
A scary @statnews Op-Ed warns that govt attempts to rein in Pharma may cut off access to "life-changing" drugs.
It takes @garyschwitzer to let us know: the author spent 10 years as Pfizer's public-policy chief. https://twitter.com/garyschwitzer/status/1360325022578053123
.@TranspariMED criticizes STAT op-ed for not disclosing pharma funding of author’s institute - similar to criticism we’ve made of STAT op-eds in the past. @transparify @ThinkTankWatch @icer_review https://www.healthnewsreview.org/2021/02/transparency-watchdog-criticizes-stats-non-disclosure-on-pro-pharma-op-ed/
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like